Clinical Significance of Elevated Levels of Soluble-Form Immune Checkpoint Molecules in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma.
Saved in:
| Title: | Clinical Significance of Elevated Levels of Soluble-Form Immune Checkpoint Molecules in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma. |
|---|---|
| Authors: | Fuji S; Department of Hematology Osaka International Cancer Institute Osaka Japan., Makiyama J; Department of Hematology Sasebo City General Hospital Nagasaki Japan., Takano K; Department of Medical Oncology & Hematology Faculty of Medicine Oita University Oita Japan., Choi I; Department of Hematology Kyushu Cancer Center Fukuoka Japan., Suzuki T; Department of Medical & Scientific Affairs, Sysmex Corporation Kobe Japan., Suminaka C; Central Research Laboratories Sysmex Corporation Kobe Japan., Kuroishi M; Central Research Laboratories Sysmex Corporation Kobe Japan., Iwasaki Y; Department of Medical & Scientific Affairs, Sysmex Corporation Kobe Japan., Kasahara H; Department of Hematology Osaka International Cancer Institute Osaka Japan., Tada Y; Department of Hematology Osaka International Cancer Institute Osaka Japan., Shingai Y; Department of Hematology Osaka International Cancer Institute Osaka Japan., Yuda S; Department of Hematology Osaka International Cancer Institute Osaka Japan., Yokota T; Department of Hematology Osaka International Cancer Institute Osaka Japan., Ishikawa J; Department of Hematology Osaka International Cancer Institute Osaka Japan. |
| Source: | EJHaem [EJHaem] 2025 Jun 26; Vol. 6 (4), pp. e70046. Date of Electronic Publication: 2025 Jun 26 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101761942 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-6146 (Electronic) Linking ISSN: 26886146 NLM ISO Abbreviation: EJHaem Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
